02591.HK
Guangzhou Innogen Pharmaceutl Grp Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.60
−0.14%Margins
Gross margin
76.0%
EBITDA margin
-255.9%
EBIT margin
-259.4%
Net margin
-266.9%
FCF margin
-260.3%
-58.4%
Return on equity
-42.4%
Return on assets
-49.0%
Return on invested capital
0.14x
Asset turnover
-HKD 598.7M
Cash from operations
HKD 2.70
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026